Ophthalmology News

Ophthal

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cohen SY – Shifting from one treatment to another is always difficult in the absence of prospective and controlled comparative studies. However, in 2009, intravitreal ranibizumab or bevacizumab may be considered as first–line therapy for sub– and juxtafoveal mCNV for three reasons: the safety of anti–VEGF drugs and intravitreal injection procedures; the disappointing long–term results of other therapies, including verteporfin treatment; and the excellent convergent results of anti–VEGF therapy in all pilot studies.

Today in Low Vision...keeping you current

Decompensated Strabismus after Bilateral Perioperative Ischaemic Optic Neuropathy with Subsequent Recovery
Neuro-Ophthalmology, 12/10/09

Binocular function in school children with reading difficulties
Graefe's Archive for Clinical and Experimental Ophthalmology, 12/10/09

The hepatocyte growth factor receptor (MET) gene is not associated with refractive error and ocular biometrics in a Caucasian population
Molecular Vision, 12/10/09

Today in Retina...keeping you current

Intravitreal Combination of Triamcinolone Acetonide and Bevacizumab (Kenacort-Avastin) in Diffuse Diabetic Macular Edema
Seminars in Ophthalmology, 12/10/09

Terson's syndrome as a prognostic factor for mortality of spontaneous subarachnoid haemorrhage
Acta Ophthalmologica, 12/10/09

Macular microcirculation before and after vitrectomy for macular edema with branch retinal vein occlusion
Graefe's Archive for Clinical and Experimental Ophthalmology, 12/10/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address